Following the requirements of the EMEA, in mBC patients ineligible for cisplatin-containing chemotherapy, PD-1/PD-L1 therapy with either atezolizumab or pembrolizumab requires the use of an FDA-approved companion diagnostic test to determine PD-L1 levels in tumor tissue. Here, PDCD1 is linked to neoplasm.